Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial

摘要

Abstract Aim The Counterweight‐Plus weight management programme achieved 46% remission of Type 2 diabetes at 1?year in the Di RECT trial. We estimated the implementation costs of the Counterweight‐Plus programme and its 1‐year cost‐effectiveness in terms of diabetes remission, compared with usual care, from the UK National Health Service ( NHS ) perspective. Methods Within‐trial total costs included programme set‐up and running costs (practitioner appointment visits, low‐energy formula diet sachets and training), oral anti‐diabetes and anti‐hypertensive medications, and healthcare contacts. Total costs were calculated for aggregated resource use for each participant and 95% confidence intervals ( CI ) were based on 1000 non‐parametric bootstrap iterations. Results One‐year programme costs under trial conditions were estimated at ￡1137 per participant (95% CI ￡1071, ￡1205). The intervention led to a significant cost‐saving of ￡120 (95% CI ￡78, ￡163) for the oral anti‐diabetes drugs and ￡14 (95% CI ￡7.9, ￡22) for anti‐hypertensive medications compared with the control. Deducting the cost‐savings of all healthcare contacts from the intervention cost resulted an incremental cost of ￡982 (95% CI ￡732, ￡1258). Cost per 1?year of diabetes remission was ￡2359 (95% CI ￡1668, ￡3250). Conclusions Remission of Type 2 diabetes within 1‐year can be achieved at a cost below the annual cost of diabetes (including complications). Providing a reasonable proportion of remissions can be maintained over time, with multiple medical gains expected, as well as immediate social benefits, there is a case for shifting resources within diabetes care budgets to offer support for people with Type 2 diabetes to attempt remission. (Clinical Trial Registry No.: ISRCTN 03267836)